Freeman Biotest Inc. Case

424 Words2 Pages

Executive Summary Many challenges face manufacturing companies today, including the introduction of a new product process and new entrants in the market that are likely to produce a similar item, as well as set a price war. In this case, most manufacturers can decide to reduce their design times, improve quality and focus on constant reductions of price for products in order to adapt to the ever changing market. Freeman Biotest Inc. is not new to these dynamic market trends and challenges in the manufacturing process. The company faces challenges in areas such as cost of processing, design capacity and quality of products. This report, therefore, focuses on explaining the situation in which Freeman Biotest Inc. is locked and recommends on how …show more content…

being successful in its total sales, it has faced certain challenges. The first major challenge that the company witnessed was inherent with the process lines. Currently, the company uses Brayford Corp. Brayford deals mainly with the equipment manufacturing; however, the line installed is prone to breakages and quality levels are questionable. In this case, the company has been grappling with the question on whether it needs to replace the line or commission it with a useful one, the Bi-Line 8. Although the Bi-Line 8 line was to be manufactured by a different company, it does not seem to offer real-time solution to the situation in which Freeman Biotest Inc is currently locked. The other challenge that the company faces is the market for its preservatives. Although the company initially sold about 48% of its products, the preservative market is currently experiencing significant changes and new entrants offer alternatives to FBXX. In this case, the current market is price sensitive thus FBXX might not do well in the market; their presence in the market is quite uncertain. Furthermore, the food preservative market is experiencing a new wave of innovation, which is a showcase that soon there will be significant changes in the

More about Freeman Biotest Inc. Case